The hereditary angioedema (HAE) market was valued at USD 3.76 billion in 2024 and is projected to reach USD 7.68 billion by 2034, growing at a CAGR of 7.40%. Growth is driven by increasing HAE prevalence across major markets and advancements in targeted therapies and preventive treatment options. https://www.expertmarketresearch.com/reports/hereditary-angioedema-market